Can we improve the clinical risk score? The prognostic value of p53, Ki-67 and thymidylate synthase in patients undergoing radical resection of colorectal liver metastases
Can we improve the clinical risk score? The prognostic value of p53, Ki-67 and thymidylate synthase in patients undergoing radical resection of colorectal liver metastases
复制标题
DOI:
10.1111/hpb.12089
复制
发表时间:
2014-03-01
期刊:
影响因子:
2.9
通讯作者:
Potrc, Stojan
中科院分区:
文献类型:
--
作者:
Ivanecz, Arpad;Kavalar, Rajko;Potrc, Stojan
ObjectivesThe aim of this study was to assess whether biological markers can provide prognostic information additional to that supplied by the clinical risk score (CRS) in patients with colorectal liver metastases.MethodsA retrospective review of a prospectively maintained database was conducted. Patients selected for this study were treated between 1996 and 2011 with potentially curative liver surgery. Expressions of p53, Ki-67 and thymidylate synthase were assayed using immunohistochemical techniques on tissue microarrays.ResultsA total of 98 (24%) of 406 patients met the inclusion criteria. The median follow-up was 103months. Analysis revealed a correlation between p53 protein overexpression and high CRS (P = 0.058). Following multivariate analysis, only high CRS remained as an independent negative prognostic predictor of survival (P = 0.018), as well as an indicator of early recurrence of disease (P = 0.010). Of the biological markers investigated, only Ki-67 overexpression was identified as a positive predictor of survival on multivariate analysis (P = 0.038).ConclusionsKi-67 overexpression was a positive predictor of survival. Only high CRS remained an independent negative prognostic predictor.